Need an investment idea? Check out Popular Stocks and S2O Stock Screener.

Market Price

17.04 

0.50 3.0%

as of Feb 15 '19

52 Week Range:

13.24 21.48


Stock Analyzer Tutorials

S2O Stock Analyzer - General Info

General Info


type: video (mp4); length: 3:30

Demonstrates how to use Stock Analyzer, shows how to analyze a stock and explains in detail "General Info" section of the Stock Analyzer result page.

S2O Stock Analyzer - Financial Statements

Financial Statements


type: video (mp4); length: 5:10

Explains information presented in the Financial Statements section of the S2O Stock Analyzer: financial statements charts, absolute values and growth rates.

S2O Stock Analyzer - Growth Grade and Financial Ratios

Growth Grade and Financial Ratios


type: video (mp4); length: 5:09

Demonstrates how to use Growth Grade & Financial Ratios section; shows the difference between historical and year-over-year Growth Grade on the real life example.

S2O Stock Analyzer - Value Price

Value Price


type: video (mp4); length: 6:03

Demonstrates how to use Value Price (intrinsic value) and the Graham Number, MOS (margin of safety) and IRT - Investment Recovery Time; explains 3 different projection models used to compute value price - pessimistic, moderate and optimistic.

S2O Stock Analyzer - Price Charts

Price Charts


type: video (mp4); length: 8:34

Demonstrates basic rules of how to read a candlestick chart, long and short term moving averages, stochastic, MACD and relative strength (RS) charts. Explains how bull or bear market condition is computed.

General Info

Halozyme Therapeutics, Inc., a biotechnology company, researches, develops, and commercializes human enzymes and other drug candidates in the United States, Switzerland, and internationally. The company's human enzymes are used to facilitate the delivery of injected drugs and fluids, enhancing the efficacy and the convenience of other drugs or can be used to alter tissue structures for clinical benefit. Its products are based on the Enhanze technology, a patented recombinant human hyaluronidase enzyme (rHuPH20) that enables the subcutaneous delivery of injectable biologics, such as monoclonal antibodies and other therapeutic molecules, as well as small molecules and fluids. The company's pipeline include Hylenex recombinant, a formulation of rHuPH20 to facilitate subcutaneous fluid administration for achieving hydration; to enhance the dispersion and absorption of other injected drugs; in subcutaneous urography; and to enhance resorption of radiopaque agents. It also develops PEGylated recombinant human hyaluronidase for the treatment of pancreatic ductal adenocarcinoma, non-small cell lung cancer, gastric cancer, metastatic breast cancer, and cholangiocarcinoma and gall bladder cancer. In addition, the company develops PEGylated adenosine deaminase 2, an immune checkpoint inhibitor that targets adenosine. It has collaborations with F. Hoffmann-La Roche, Ltd.; Hoffmann-La Roche, Inc.; Baxalta US Inc.; Baxalta GmbH; Pfizer Inc.; Janssen Biotech, Inc.; AbbVie, Inc.; Eli Lilly and Company; Bristol-Myers Squibb Company; and Alexion Pharma Holding. Halozyme Therapeutics, Inc. was founded in 1998 and is headquartered in San Diego, California.

Financial Statements

The charts below show selected Annual and Quarterly Financial Data.

The purpose of these charts is to discover long and short term change dynamics. When numbers are growing year after year in the annual statements chart, the business become stronger and stronger and this is a good sign.

Quarterly Data Chart can be used to do a short term analysis. It makes sense to pay attention to the quarterly dynamics and do not wait for the next yearly statement. We should be alerted if we see that quarterly numbers are going down.

You can check "Annual Financial Statements" and "Quarterly Financial Statements" sections for exact numbers and growth rates.

Annual Statements

On a charts below the Line shows absolute values and the Bar chart shows Year-Over-Year Growth Rate for selected financial statement item. A consistent GROWTH is generally considered necessary to fund future growth from within a business.
NOTE: Growth Rate is not provided if either the latest period or the year-ago period contains a net loss. (source: WSJ Digest of Earnings)
TIP! move your mouse pointer over bar or a circle on any chart below to see details.

Financial Statements

Income Statement



 

Cash Flow Statement



 

Balance Sheet



 

Liquidity Ratios

Current Ratio


 

Current Ratio measures the ability to meet short term obligations. Generally accepted standard is 2 (current assets should be 2 times or 200% of current liabilities).

Quick Ratio


 

Measures immediate liquidity or the cash available to cover immediate liabilities. A safe margin would be at least 1 (100%).

Financial Leverage


 

Defined as total assets divided by total shareholders' equity. The higher the ratio, the more debt a company uses in its capital structure.

Profitability Ratios

ROA


 

Return on Assets (ROA) measures the income (profit) that is generated by the use of the assets of the business.

ROE


 

Return on Equity (ROE) is a measure of profitability that calculates how many dollars of profit a company generates with each dollar of shareholders equity. ROE is sometimes called "return on net worth."

ROIC


 

The Return on Invested Capital (ROIC) measure gives a sense of how well a company is using its money to generate returns. Some investors use this figure as a final evaluation to determine whether or not to invest in a company.

Annual Statements

Item Name Dec '07 Dec '08 Dec '09 Dec '10 Dec '11 Dec '12 Dec '13 Dec '14 Dec '15 Dec '16 Dec '17
Equity (BVPS) 0.74
0.19
0.08
0.20
0.26
0.43
-0.03
0.32
0.25
-0.09
0.51
growth rate -74.3% -57.9% 150.0% 30.0% 65.4% -100.0% 100.0% -21.9% -100.0% 100.0%
Earnings BIT -23.90
-48.72
-58.36
-53.24
-19.77
-53.60
-80.20
-61.84
-27.45
-83.21
81.00
growth rate 0.0% 0.0% 0.0% 0.0% 0.0% 0.0% 0.0% 0.0% 0.0% 100.0%
Avg.PE -27.30
-9.60
-9.50
-12.70
-36.90
-17.10
-5.38
-5.38
-5.38
-5.38
-18.58
growth rate 0.0% 0.0% 0.0% 0.0% 0.0% 0.0% 0.0% 0.0% 0.0% 0.0%
ROA -31.96
-54.05
-75.93
-63.20
-25.17
-53.42
-70.59
-51.07
-18.54
-46.48
16.12
growth rate 0.0% 0.0% 0.0% 0.0% 0.0% 0.0% 0.0% 0.0% 0.0% 100.0%
ROE -59.11
-133.03
-523.80
-390.69
-126.52
-179.24
-578.45
-640.18
-76.42
71.60
growth rate 0.0% 0.0% 0.0% 0.0% 0.0% 0.0% 0.0% 0.0% 100.0%
ROIC -69.64
-133.03
-524.68
-390.69
-126.52
-87.90
-146.16
-103.80
-26.25
-60.13
28.40
growth rate 0.0% 0.0% 0.0% 0.0% 0.0% 0.0% 0.0% 0.0% 0.0% 100.0%
Cur. Ratio 11.41
5.21
5.17
5.83
3.70
6.92
3.74
6.63
2.75
4.70
3.89
growth rate -54.3% -0.8% 12.8% -36.5% 87.0% -46.0% 77.3% -58.5% 70.9% -17.2%
Quick Ratio 11.11
4.99
4.98
5.58
3.18
6.10
3.17
5.95
2.25
4.04
3.74
growth rate -55.1% -0.2% 12.1% -43.0% 91.8% -48.0% 87.7% -62.2% 79.6% -7.4%
Leverage 1.79
4.98
11.18
4.49
6.03
2.76
4.01
4.23
2.50
growth rate 178.2% 124.5% -59.8% 34.3% -54.2% 20.5% 5.5% -23.1%
Balance Sheet Dec '07 Dec '08 Dec '09 Dec '10 Dec '11 Dec '12 Dec '13 Dec '14 Dec '15 Dec '16 Dec '17
Acct.Receivable 7.30
4.20
2.30
2.26
15.70
9.10
9.15
32.41
15.68
22.13
growth rate -42.5% -45.2% -1.7% 594.1% -42.0% 0.5% 254.3% -51.6% 41.2%
Acct.Payable 13.17
2.30
3.10
3.00
4.50
3.58
7.95
growth rate -82.5% 34.8% -3.1% 49.8% -20.5% 122.1%
Cur.Assets 74.00
74.40
89.50
63.99
131.00
95.20
161.32
171.77
256.53
510.37
growth rate 0.5% 20.3% -28.5% 104.7% -27.3% 69.5% 6.5% 49.3% 99.0%
Total Assets 76.60
77.10
91.30
65.76
134.70
101.80
165.98
181.79
261.52
519.95
growth rate 0.7% 18.4% -28.0% 104.8% -24.4% 63.0% 9.5% 43.9% 98.8%
Cash 63.70
67.50
83.30
52.83
99.90
27.40
61.39
43.29
66.76
168.74
growth rate 6.0% 23.4% -36.6% 89.1% -72.6% 124.1% -29.5% 54.2% 152.7%
Inventory 0.40
1.20
0.20
0.57
2.70
6.20
6.41
9.49
14.62
5.15
growth rate 200.0% -83.3% 183.5% 376.2% 129.6% 3.3% 48.1% 54.1% -64.8%
Cur.Liabilities 14.20
14.40
15.30
17.30
18.90
25.50
24.33
62.46
54.59
131.33
growth rate 1.4% 6.3% 13.1% 9.2% 34.9% -4.6% 156.7% -12.6% 140.6%
Liabilities 61.20
70.20
71.00
54.86
85.90
121.80
124.63
138.79
294.00
311.58
growth rate 14.7% 1.1% -22.7% 56.6% 41.8% 2.3% 11.4% 111.8% 6.0%
LT Debt 0.00
0.00
0.00
0.00
0.00
29.70
49.80
49.86
27.97
199.23
125.14
growth rate 67.7% 0.1% -43.9% 612.3% -37.2%
Equity 57.77
15.40
6.90
20.40
10.90
48.90
41.35
43.00
-32.48
208.37
growth rate -73.3% -55.2% 195.7% -46.6% 348.6% -8.0% 4.0% -100.0% 100.0%
Common Shares 74.00
80.00
87.00
94.00
103.00
111.00
113.00
123.00
127.00
128.00
139.00
growth rate 8.1% 8.8% 8.1% 9.6% 7.8% 1.8% 8.9% 3.3% 0.8% 8.6%
Cash Flow Statement Dec '07 Dec '08 Dec '09 Dec '10 Dec '11 Dec '12 Dec '13 Dec '14 Dec '15 Dec '16 Dec '17
Capital Expenditures 2.37
1.20
1.50
0.60
0.83
1.41
2.30
1.37
2.36
3.14
1.35
growth rate -49.4% 25.0% -60.0% 38.2% 70.5% 62.6% -40.4% 72.5% 32.9% -57.0%
Cash Dividends 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
growth rate
Cash From OA -0.15
-35.37
-40.15
-45.39
-34.35
-64.33
-47.52
-37.08
-50.38
134.05
growth rate 0.0% 0.0% 0.0% 0.0% 0.0% 0.0% 0.0% 0.0% 100.0%
FCF per Share -0.03
-0.46
-0.48
-0.49
-0.28
-0.59
-0.47
-0.54
-0.19
-0.42
-0.27
growth rate 0.0% 0.0% 0.0% 0.0% 0.0% 0.0% 0.0% 0.0% 0.0% 0.0%
Sale Purchase of Stock 4.75
0.00
0.00
114.50
13.10
1.87
147.65
growth rate -100.0% -88.6% -85.8% 7,816.9%
FCF -3.00
-37.00
-42.00
-46.00
-35.00
-66.00
-52.00
-49.00
-39.00
-54.00
133.00
growth rate 0.0% 0.0% 0.0% 0.0% 0.0% 0.0% 0.0% 0.0% 0.0% 100.0%
Income Statement Dec '07 Dec '08 Dec '09 Dec '10 Dec '11 Dec '12 Dec '13 Dec '14 Dec '15 Dec '16 Dec '17
Sales 3.80
8.80
13.70
13.60
56.09
42.30
54.80
75.33
135.06
146.69
316.61
growth rate 131.6% 55.7% -0.7% 312.4% -24.6% 29.6% 37.5% 79.3% 8.6% 115.8%
Op.Income -50.40
-58.50
-54.30
-19.77
-53.60
-83.50
-61.84
-27.45
-83.21
81.00
growth rate 0.0% 0.0% 0.0% 0.0% 0.0% 0.0% 0.0% 0.0% 100.0%
IBT -48.70
-58.40
-53.20
-19.77
-53.60
-83.50
-68.38
-32.23
-101.86
61.61
growth rate 0.0% 0.0% 0.0% 0.0% 0.0% 0.0% 0.0% 0.0% 100.0%
Net Income -48.70
-58.40
-53.20
-19.77
-53.60
-83.50
-68.38
-32.23
-103.02
62.97
growth rate 0.0% 0.0% 0.0% 0.0% 0.0% 0.0% 0.0% 0.0% 100.0%
EPS -0.32
-0.61
-0.67
-0.56
-0.19
-0.48
-0.74
-0.56
-0.25
-0.81
0.45
growth rate 0.0% 0.0% 0.0% 0.0% 0.0% 0.0% 0.0% 0.0% 0.0% 100.0%
Gross Profit 3.56
8.40
13.40
12.60
55.83
42.30
48.60
-25.99
12.58
-37.36
134.82
growth rate 136.0% 59.5% -6.0% 343.1% -24.2% 14.9% -100.0% 100.0% -100.0% 100.0%
R&D 44.20
56.60
51.80
57.56
70.00
96.60
79.70
93.24
150.84
150.64
growth rate 28.1% -8.5% 11.1% 21.6% 38.0% -17.5% 17.0% 61.8% -0.1%

Quarterly Statements

Item Name Sep '17 Dec '17 Mar '18 Jun '18 Sep '18
Earnings BIT 8.08
125.93
-23.71
-20.07
-25.47
growth rate 1,459.1% -100.0% 0.0% 0.0%
Balance Sheet Sep '17 Dec '17 Mar '18 Jun '18 Sep '18
Acct.Receivable 14.70
22.13
26.57
33.58
27.66
growth rate 50.6% 20.1% 26.4% -17.7%
Acct.Payable 4.15
7.95
3.63
6.19
3.33
growth rate 91.4% -54.4% 70.5% -46.2%
Cur.Assets 353.35
510.37
484.47
462.03
429.93
growth rate 44.4% -5.1% -4.6% -7.0%
Total Assets 357.15
519.95
495.47
474.75
444.51
growth rate 45.6% -4.7% -4.2% -6.4%
Cash 164.40
168.74
98.01
55.17
55.02
growth rate 2.6% -41.9% -43.7% -0.3%
Inventory 9.33
5.15
4.39
8.40
18.29
growth rate -44.9% -14.6% 91.3% 117.6%
Cur.Liabilities 102.05
131.33
119.22
132.43
139.12
growth rate 28.7% -9.2% 11.1% 5.1%
Liabilities 284.76
311.58
230.41
219.83
204.77
growth rate 9.4% -26.1% -4.6% -6.9%
LT Debt 145.42
125.14
102.70
79.08
57.94
growth rate -13.9% -17.9% -23.0% -26.7%
Equity 72.39
208.37
265.06
254.93
239.74
growth rate 187.8% 27.2% -3.8% -6.0%
Common Shares 0.14
0.14
0.14
0.14
0.15
growth rate 0.7% 0.7% 0.0% 0.7%
Cash Flow Statement Sep '17 Dec '17 Mar '18 Jun '18 Sep '18
Capital Expenditures 0.16
0.86
0.84
0.42
0.33
growth rate 434.2% -2.4% -50.2% -20.3%
Cash Dividends
growth rate
Cash From OA 20.26
153.25
-22.18
-18.86
-18.93
growth rate 656.5% -100.0% 0.0% 0.0%
Sale Purchase of Stock 3.71
5.09
4.98
3.14
growth rate 37.4% -2.2% -36.9%
FCF 20.10
152.39
-23.02
-19.28
-19.26
growth rate 658.2% -100.0% 0.0% 0.0%
Income Statement Sep '17 Dec '17 Mar '18 Jun '18 Sep '18
Sales 63.73
189.56
30.87
35.20
25.56
growth rate 197.4% -83.7% 14.0% -27.4%
Op.Income 8.08
125.93
-23.71
-20.07
-25.47
growth rate 1,459.1% -100.0% 0.0% 0.0%
IBT 3.33
121.55
-27.27
-22.86
-27.85
growth rate 3,551.3% -100.0% 0.0% 0.0%
Net Income 2.75
123.88
-27.46
-22.89
-27.85
growth rate 4,406.4% -100.0% 0.0% 0.0%
EPS
growth rate
Gross Profit 21.41
140.70
-10.16
-5.72
-10.61
growth rate 557.3% -100.0% 0.0% 0.0%
R&D 40.09
40.09
40.09
40.09
growth rate 0.0% 0.0% 0.0%

Growth Grade & Financial Ratios

All financial ratios below are calculated based on latest annual statements available and present the most up to date snapshot of a company finances.

Growth Grade

Historical Growth Grade:

B (75.42)

YOY Growth Grade:

F (8.93)

Click on buttons above for detailed yearly growth rates.

Market Ratios

Profitability Ratios

Liquidity Ratios

Efficiency Ratios

Value Price

PE and EPS

Historical Current Forward
PE 53.03 56.05 -24.80
EPS / Growth 0.0% 0.30 55.0%

Value Price & Investment Recovery Time

Read more about Stock2Own value price in Stock Market: Fundamental Analysis.

Equity Growth Rate: 50.0%

Estimates Pessimistic Moderate Optimistic My Numbers
Rate of Return 15.0%
MOS Price % 50 %
Future EPS Growth 0.0% 35.0% 38.5%
Future PE 0.00 41.01 43.33
Future EPS 0.30 6.11 7.88
Value Price
MOS %
0.00
-100.0%
61.97
263.7%
84.37
395.2%
MOS Price 0.00 30.98 42.19
IRT 56.05 9.12 8.59

Graham Number:

NOTE: The Graham Number applies only to certain types of stocks in combination with a number of other criteria.

Read more about Graham Number in Stock Market: Fundamental Analysis.

Price Chart

The functionality you are trying to reach is available to registered users only.

Login to your account or Register Now if you are not registered yet. Registration is FREE and will take only a minute.

Risk / Reward Ratios

The functionality you are trying to reach is available to registered users only.

Login to your account or Register Now if you are not registered yet. Registration is FREE and will take only a minute.